Lumida
/TMDX
⌘K
Transmedics Group Inc

Transmedics Group Inc

TMDX
$82.18USD-3.36%-2.86 today

MARKET CAP

2.8B

P/E (TTM)

18.8x

FWD P/E

DAY RANGE

$79 – $86

52W RANGE

$60
$156

AI Summary

Stalk
Sell NowMedium

TMDX has broken below key moving averages and failed to sustain its recent advance, shifting the medium-term bias to bearish while the long-term trend remains negative under a declining 200DMA. Short-term momentum confirms the downside as price rejects EMAs and RSI turns down. Execution favors selling on rallies into the former support-turned-resistance zone.

  • Q2 revenue of $190 M grew 21% YoY, led by 29% service revenue growth
  • Full-year 2026 revenue guidance increased 22–25% YoY to $737–757 M
  • EPS down 52% YoY amid rising operating expenses
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$30.3M$93.5M$241.6M$441.5M$605.5M
YoY %+18.0%+208.8%+158.5%+82.7%+37.1%
P / Sales17.5x18.1x10.3x5.0x8.1x
EV / Sales18.9x16.9x11.1x5.5x8.3x
Gross Profit, Adj.$21.2M$65.3M$154.1M$262.1M$362.8M
YoY %+27.2%+208.5%+136.1%+70.1%+38.4%
Margin %69.9%69.8%63.8%59.4%59.9%
EV / Gross Profit27.0x24.2x17.3x9.3x13.9x
EBITDA, Adj.$-37.6M$-28.0M$-20.6M$57.3M$135.8M
YoY %-51.6%+25.7%+26.5%+378.6%+137.1%
Margin %-124.3%-29.9%-8.5%13.0%22.4%
EV / EBITDA-15.2x-56.4x-130.0x42.5x37.1x
EBIT$-39.4M$-31.4M$-28.7M$37.5M$108.6M
YoY %-49.4%+20.3%+8.6%+230.5%+189.6%
Margin %-130.3%-33.6%-11.9%8.5%17.9%
EV / EBIT-14.5x-50.2x-93.0x64.9x46.4x
Net Income$-44.2M$-36.2M$-25.0M$35.5M$190.3M
YoY %-53.8%+18.1%+30.9%+241.7%+436.6%
Net Margin-146.1%-38.8%-10.4%8.0%31.4%
EPS (GAAP)-$1.60-$1.23-$0.77$1.01$4.87
YoY %-37.9%+23.1%+37.4%+231.2%+382.2%